Direct-to-consumer personal genome testing: ethical and regulatory issues that arise from wanting to 'know' your DNA.

摘要: Direct-to-consumer personal genome testing (DTC-PGT) screens a customer's for the presence of single nucleotide polymorphisms that are reported to be associated with various diseases, disease risk factors and characteristics. The range health risks covered by (PGT) includes cancer, heart disease, obesity, diabetes mellitus osteoporosis. PGT also detects other characteristics, such as alcohol 'flush reaction', eye colour, ear wax type bitter taste perception. Information about ancestry family history is available. Although DTC-PGT still relatively new enterprise, technology has potential rapid expansion it becomes more accessible consumers who wish obtain information their genetic profile. This review provides an overview broader ethical regulatory issues raised tests marketed directly public, purport provide risks. We discuss emergence in Australia, possible responses may taken manage it.